Source comparison
Tesamorelin Lipodystrophy Complete Guide 2026: Clinical Outcomes Comparison
| Intervention | Mean VAT Reduction (26 weeks) | Subcutaneous Fat Impact | Lean Mass Change | Durability After Discontinuation | Primary Mechanism | Professional Assessment ||—|—|—|—|—|—|| Tesamorelin 2mg daily | 15.2–17.9% (−18.3 cm² absolute) | No significan
This comparison does not assign a generated winner or score.
- | Intervention | Mean VAT Reduction (26 weeks) | Subcutaneous Fat Impact | Lean Mass Change | Durability After Discontinuation | Primary Mechanism | Professional Assessment ||—|—|—|—|—|—|| Tesamorelin 2mg daily | 15.2–17.9% (−18.3 cm² absolute) | No significant change | +0.8 kg increase | Returns to baseline within 26 weeks | GHRH-mediated pulsatile GH release targeting visceral adipocytes | Gold standard for HIV lipodystrophy VAT reduction—effect is treatment-dependent, not permanent || Lifestyle modification (diet + exercise) | 3–7% (highly variable) | Proportional reduction across all depots | Variable (−1 to +2 kg depending on protocol) | Maintained only with ongoing adherence | Caloric deficit and increased energy expenditure | Effective for overall adiposity but lacks regional selectivity—difficult to sustain long-term || GLP-1 agonists (semaglutide, tirzepatide) | 8–12% total body fat (not VAT-specific) | Proportional reduction across subcutaneous and visceral depots | Slight de